Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | METAP2 | P50579 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 2/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | MIF | P14174 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 3/20 | 0.39 |
| ▸ | BCAT2 | O15382 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.39 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.39 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31141922 | 1.00 | METAP2 (0.45) | METAP2KDM4EALDH1A1LMNATSHR | |
| SCHEMBL3787249 | 0.84 | KDM4E (0.52) | METAP2KDM4EALDH1A1LMNATSHR | |
| SCHEMBL1552127 | 0.81 | ALDH1A1 (0.43) | ALDH1A1TSHRHPGDMIFKMT2A | |
| SCHEMBL156051 | 0.81 | TSHR (0.63) | KDM4EALDH1A1LMNATSHRHPGD | |
| SCHEMBL16914408 | 0.79 | KDM4E (0.44) | METAP2KDM4EALDH1A1LMNATSHR | |
| SCHEMBL2063058 | 0.79 | TSHR (0.41) | ALDH1A1LMNATSHRMIFKMT2A | |
| SCHEMBL29746220 | 0.79 | CA1 (0.47) | KDM4EALDH1A1LMNAMAPTMIF | |
| SCHEMBL3142731 | 0.79 | CA1 (0.47) | KDM4EALDH1A1LMNAMAPTMIF | |
| SCHEMBL29787113 | 0.78 | TSHR (0.65) | KDM4EALDH1A1LMNATSHRMAPT | |
| SCHEMBL3170417 | 0.78 | METAP2 (0.48) | METAP2KDM4EALDH1A1TSHRMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113461538-A | Preparation method of 2-chloro-3-bromoaniline | 无锡双启科技有限公司 | 2021-10-01 | — | — | CN | disclosed |
| CN-108349996-A | Tricyclic PI3K inhibitor compounds and methods of use thereof | 豪夫迈·罗氏有限公司 | 2018-07-31 | — | — | CN | disclosed |
| CN-107674073-A | 3,5 2 as protein kinase modulators substitute 3H imidazoles (or [1,2,3] triazole) simultaneously [4,5 B] pyridine compounds | 印蔻真治疗公司 | 2018-02-09 | — | — | CN | disclosed |
| CN-103214471-B | The preparation method of compound with Na-dependent glucose transporter inhibitory activity | 田边三菱制药株式会社 | 2018-02-06 | — | — | CN | disclosed |
| CN-103068824-B | Novel 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridines and 3, 5-disubstituted-3H- [1,2,3] triazolo [4,5-B ] pyridine compounds as protein kinase modulators | 印蔻真治疗公司 | 2017-09-08 | — | — | CN | disclosed |
| CN-107082779-A | It is used as the noval chemical compound of C MET protein kinase modulators | 理森制药股份公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-106795100-A | Compound, pharmaceutical composition and its purposes in nerve degenerative diseases are treated | 法国里尔第二大学 | 2017-05-31 | — | — | CN | disclosed |
| CN-105473556-A | Strobilurin-type compounds for controlling phytopathogenic fungi | BASF SE | 2016-04-06 | — | — | CN | disclosed |
| CN-104321322-A | Novel 3, 5-disubstituted-3H-imidazo [4,5-B ] pyridines and 3, 5-disubstituted-3H- [1,2,3] triazolo [4,5-B ] pyridines as modulators of C-MET protein kinase | RHIZEN PHARMACEUTICALS SA | 2015-01-28 | — | — | CN | disclosed |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | GLAXOSMITHKLINE LLC | 2014-10-30 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| US-8633175-B2 | Compounds as antagonists or inverse agonists at opioid receptors | GLAXOSMITHKLINE LLC (US) | 2014-01-21 | — | — | US | disclosed |
| WO-2014008214-A1 | BIARYL-CONTAINING COMPOUNDS AS INVERSE AGONISTS OF ROR-GAMMA RECEPTORS | BIOGEN IDEC MA INC. (US) | 2014-01-09 | — | — | WO | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2011-05-26 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | IGNAR DIANE MICHELE | 2010-05-06 | — | — | US | disclosed |
| WO-2008021849-A2 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2008-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110124559-A1 | NOVEL COMPOUNDS AS ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRM1, OPRK1 | METAP2 1187/4885KDM4E 3829/4885ALDH1A1 3500/4885 |
| US-20100113512-A1 | METHOD OF TREATMENT USING NOVEL ANTAGONISTS OR INVERSE AGONISTS AT OPIOID RECEPTORS | OPRL1, OPRD1, OPRK1 | METAP2 1031/4885KDM4E 2806/4885ALDH1A1 4254/4885 |
| US-20140323487-A1 | Novel Compounds As Antagonists Or Inverse Agonists At Opioid Receptors | OPRL1, OPRM1, OPRK1 | METAP2 1187/4885KDM4E 3829/4885ALDH1A1 3500/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.